Santen Pharmaceutical Co., Ltd. (TYO:4536)
Japan
· Delayed Price · Currency is JPY 1,551.00
-5.50 (-0.35%)
At close: Dec 5, 2025
Santen Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 291,479 | 300,004 | 301,965 | 279,037 | 266,257 | 249,605 | Upgrade
|
| Revenue Growth (YoY) | -3.66% | -0.65% | 8.22% | 4.80% | 6.67% | 3.33% | Upgrade
|
| Cost of Revenue | 126,149 | 128,977 | 123,256 | 112,950 | 109,671 | 98,221 | Upgrade
|
| Gross Profit | 165,330 | 171,027 | 178,709 | 166,087 | 156,586 | 151,384 | Upgrade
|
| Selling, General & Admin | 83,601 | 83,299 | 86,880 | 134,072 | 120,610 | 113,586 | Upgrade
|
| Research & Development | 25,530 | 24,103 | 25,416 | - | - | - | Upgrade
|
| Other Operating Expenses | 229 | 1,638 | -282 | -3,285 | 101 | -15,710 | Upgrade
|
| Operating Expenses | 122,993 | 122,732 | 126,524 | 130,787 | 120,711 | 97,876 | Upgrade
|
| Operating Income | 42,337 | 48,295 | 52,185 | 35,300 | 35,875 | 53,508 | Upgrade
|
| Interest Expense | -1,204 | -1,083 | -831 | -476 | -249 | -159 | Upgrade
|
| Interest & Investment Income | 1,499 | 1,623 | 1,262 | 1,086 | 1,063 | 928 | Upgrade
|
| Earnings From Equity Investments | -685 | -685 | -7,575 | -2,362 | -1,604 | -358 | Upgrade
|
| Currency Exchange Gain (Loss) | 1,651 | 1,651 | -121 | -663 | -959 | -910 | Upgrade
|
| Other Non Operating Income (Expenses) | 13 | 15 | -198 | -118 | 371 | -120 | Upgrade
|
| EBT Excluding Unusual Items | 43,611 | 49,816 | 44,722 | 32,767 | 34,497 | 52,889 | Upgrade
|
| Merger & Restructuring Charges | - | - | -5,829 | -3,225 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -708 | -708 | -1,046 | -228 | 800 | -119 | Upgrade
|
| Gain (Loss) on Sale of Assets | -286 | -286 | 738 | -554 | 412 | -102 | Upgrade
|
| Asset Writedown | -1,302 | -1,302 | -7,547 | -34,508 | 245 | -40,250 | Upgrade
|
| Legal Settlements | - | - | -410 | -51 | -338 | - | Upgrade
|
| Other Unusual Items | -39 | -39 | -755 | - | - | - | Upgrade
|
| Pretax Income | 41,276 | 47,481 | 29,873 | -5,799 | 35,616 | 12,418 | Upgrade
|
| Income Tax Expense | 10,273 | 11,628 | 3,171 | 9,184 | 8,427 | 5,773 | Upgrade
|
| Earnings From Continuing Operations | 31,003 | 35,853 | 26,702 | -14,983 | 27,189 | 6,645 | Upgrade
|
| Minority Interest in Earnings | 421 | 403 | -60 | 35 | 29 | 185 | Upgrade
|
| Net Income | 31,424 | 36,256 | 26,642 | -14,948 | 27,218 | 6,830 | Upgrade
|
| Preferred Dividends & Other Adjustments | 10 | 9 | 8 | 7 | 6 | 4 | Upgrade
|
| Net Income to Common | 31,414 | 36,247 | 26,634 | -14,955 | 27,212 | 6,826 | Upgrade
|
| Net Income Growth | 20.25% | 36.09% | - | - | 298.51% | -71.08% | Upgrade
|
| Shares Outstanding (Basic) | 338 | 349 | 367 | 387 | 400 | 399 | Upgrade
|
| Shares Outstanding (Diluted) | 339 | 350 | 368 | 387 | 400 | 400 | Upgrade
|
| Shares Change (YoY) | -5.30% | -5.01% | -4.98% | -3.26% | 0.02% | 0.03% | Upgrade
|
| EPS (Basic) | 92.94 | 103.98 | 72.59 | -38.60 | 68.07 | 17.09 | Upgrade
|
| EPS (Diluted) | 92.73 | 103.68 | 72.37 | -38.60 | 67.97 | 17.06 | Upgrade
|
| EPS Growth | 26.97% | 43.26% | - | - | 298.44% | -71.09% | Upgrade
|
| Free Cash Flow | 38,822 | 54,266 | 63,330 | 19,870 | 28,699 | 34,669 | Upgrade
|
| Free Cash Flow Per Share | 114.56 | 155.18 | 172.03 | 51.29 | 71.67 | 86.59 | Upgrade
|
| Dividend Per Share | 38.000 | 36.000 | 33.000 | 32.000 | 32.000 | 28.000 | Upgrade
|
| Dividend Growth | -24.00% | 9.09% | 3.13% | - | 14.29% | 3.70% | Upgrade
|
| Gross Margin | 56.72% | 57.01% | 59.18% | 59.52% | 58.81% | 60.65% | Upgrade
|
| Operating Margin | 14.52% | 16.10% | 17.28% | 12.65% | 13.47% | 21.44% | Upgrade
|
| Profit Margin | 10.78% | 12.08% | 8.82% | -5.36% | 10.22% | 2.73% | Upgrade
|
| Free Cash Flow Margin | 13.32% | 18.09% | 20.97% | 7.12% | 10.78% | 13.89% | Upgrade
|
| EBITDA | 60,431 | 66,243 | 70,363 | 52,549 | 52,930 | 70,276 | Upgrade
|
| EBITDA Margin | 20.73% | 22.08% | 23.30% | 18.83% | 19.88% | 28.16% | Upgrade
|
| D&A For EBITDA | 18,094 | 17,948 | 18,178 | 17,249 | 17,055 | 16,768 | Upgrade
|
| EBIT | 42,337 | 48,295 | 52,185 | 35,300 | 35,875 | 53,508 | Upgrade
|
| EBIT Margin | 14.52% | 16.10% | 17.28% | 12.65% | 13.47% | 21.44% | Upgrade
|
| Effective Tax Rate | 24.89% | 24.49% | 10.62% | - | 23.66% | 46.49% | Upgrade
|
| Advertising Expenses | - | 13,310 | 18,278 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.